Unlocking the Promise of Genome Editing to DeliverĀ Life-Changing Medicines

Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Read More


Editas News

April 15, 2014
Editas Medicine Co-Founder is awarded First Patent for Engineered CRISPR-Cas9 System   Read More

February 13, 2014
Editas Medicine Co-Founder Publishes Key CRISPR Complex Structure in Cell Read More

February 7, 2014
Editas Medicine Co-founder Publishes High-Resolution Structures of Major Cas9 Enzymes in Science Read More

January 27, 2014
Editas Medicine Co-founder Develops Novel Approach to Increase Specificity of CRISPR/Cas9 Technology; Findings Published in Nature Biotechnology Read More


February 13, 2014
Cell: Crystal structure of Cas9 in complex with guide RNA and target DNA. Read More

February 6, 2014
Science: Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Read More

January 29, 2014
Nature: DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Read More

January 26, 2014
Nature Biotechnology: Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Read More